Company intelligence / Profile preview

CYTLIMIC

Shinagawa City, Tokyo, Japanimmutep.com ↗

Ownership: Private
Development stage: Phase 1

Overview

CYTLIMIC develops novel immunotherapy products, primarily therapeutic peptide vaccines for cancer. Its lead candidate, CYT001, targets liver cancer and has advanced to Phase II clinical trials. The company leverages proprietary AI technology from NEC to rapidly discover and optimize new vaccine candidates tailored to genetic profiles common in Japan. Early results show promise for safety and efficacy in activating anti-tumor immune responses.

Therapeutic areas: Oncology
Modalities: Peptide vaccinesImmunostimulantsBiological products
Industry: Biotech

Drug pipeline

1 asset

CYT001

Unknown

Partnerships

NEC CorporationYamaguchi UniversityKochi UniversityFast Track Initiative Inc.SMBC Venture Capital Co., Ltd.NEC Capital Solutions LimitedPrima Biomed

Beyond the preview

Go deeper on CYTLIMIC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYTLIMIC.

Explore the full profile